昊海生科20240715

Summary of Conference Call on Haohai Biological Technology Company Overview - The conference call discusses Haohai Biological Technology, focusing on its innovative fourth-generation hyaluronic acid product, "Yuebai" [1][5]. Key Points and Arguments Product Innovation - The new product, Yuebai, is positioned as a revolutionary advancement in hyaluronic acid fillers, marking the transition to the 2.0 era of hyaluronic acid [1]. - Yuebai utilizes lysine as a cross-linking agent, enhancing biocompatibility and long-term safety compared to traditional chemical cross-linkers [1][2]. - The introduction of amino acid cross-linkers improves the product's structure, promoting cell adhesion and proliferation, thus enhancing its regenerative properties [2][4]. - The product has received international PCT patent approval, making it the first fully autonomous innovation from China in this field [5]. Market Strategy - The company has been preparing for the product's market launch for three years, generating anticipation among medical professionals [16]. - Sales training, product packaging, and pricing strategies are actively being developed, with a planned market launch in October [17][21]. - The pricing strategy aims for a mid-to-high range to ensure profitability while remaining accessible to consumers [19][20]. Sales and Growth Expectations - The company anticipates significant sales growth, projecting over 300 million yuan in sales for the year, largely driven by overseas markets [25]. - The introduction of Yuebai is expected to complement existing products without cannibalizing their sales, aiming for simultaneous growth [26][27]. Industry Context - The medical aesthetics industry is facing challenges due to consumer spending declines and price wars among institutions [39][41]. - Haohai aims to differentiate itself through continuous innovation and a diverse product line, including energy devices and skin rejuvenation solutions [30][32]. R&D and Future Plans - The company is committed to ongoing R&D, focusing on a wide range of products from skin treatments to energy devices [55][58]. - Future product lines will include various hyaluronic acid formulations and botulinum toxin products, with plans for clinical trials and market launches in the coming years [61][62]. Collaboration and Partnerships - Strategic partnerships with major medical aesthetic institutions, such as Meilai Group, are in place to promote the new product line [9][20]. - The company is also exploring international markets, with plans to introduce its products to Europe and the U.S. [50]. Additional Important Information - The company emphasizes the importance of safety and efficacy in its products, aiming to lead the market with innovative solutions [62][67]. - Haohai is focused on building a comprehensive marketing strategy that integrates online and offline channels to enhance brand visibility and consumer engagement [49][50]. This summary encapsulates the key discussions and strategic insights shared during the conference call, highlighting Haohai Biological Technology's innovative approach and market positioning in the medical aesthetics industry.